pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-18. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
=== Erroneous and incomplete discoveries === In 1914, Stefan Meyer, Viktor F. Hess, and Friedrich Paneth (working in Vienna) made measurements of alpha radiation from various substances, including 227Ac. They observed the possibility of a minor alpha branch of this nuclide, though follow-up work could not be done due to the outbreak of World War I. Their observations were not precise and sure enough for them to announce the discovery of element 87, though it is likely that they did indeed observe the decay of 227Ac to 223Fr. Soviet chemist Dmitry Dobroserdov was the first scientist to claim to have found eka-caesium, or francium. In 1925, he observed weak radioactivity in a sample of potassium, another alkali metal, and incorrectly concluded that eka-caesium was contaminating the sample (the radioactivity from the sample was from the naturally occurring potassium radioisotope, potassium-40). He then published a thesis on his predictions of the properties of eka-caesium, in which he named the element russium after his home country. Shortly thereafter, Dobroserdov began to focus on his teaching career at the Polytechnic Institute of Odesa, and he did not pursue the element further. The following year, English chemists Gerald J. F. Druce and Frederick H. Loring analyzed X-ray photographs of manganese(II) sulfate. They observed spectral lines which they presumed to be of eka-caesium. They announced their discovery of element 87 and proposed the name alkalinium, as it would be the heaviest alkali metal.
AMPK activation is required for an increase in the expression of small heterodimer partner, which in turn inhibited the expression of the hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase and glucose 6-phosphatase. Metformin is frequently used in research along with AICA ribonucleotide as an AMPK agonist. The mechanism by which biguanides increase the activity of AMPK remains uncertain: metformin increases the concentration of cytosolic adenosine monophosphate (AMP) (as opposed to a change in total AMP or total AMP/adenosine triphosphate) which could activate AMPK allosterically at high levels; a newer theory involves binding to PEN-2. Metformin inhibits cyclic AMP production, blocking the action of glucagon, and thereby reducing fasting glucose levels. Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice, and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion. In addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral glucose uptake (by inducing the phosphorylation of GLUT4 enhancer factor), decreases insulin-induced suppression of fatty acid oxidation, and decreases the absorption of glucose from the gastrointestinal tract. Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors. The increase in insulin binding after metformin treatment has also been demonstrated in patients with type 2 diabetes.
== History == Pepsin was one of the first enzymes to be discovered by Theodor Schwann in 1836. Schwann coined its name from the Greek word πέψις pepsis, meaning "digestion" (from πέπτειν peptein "to digest"). An acidic substance that was able to convert nitrogen-based foods into water-soluble material was determined to be pepsin. In 1928, it became one of the first enzymes to be crystallized when John H. Northrop crystallized it using dialysis, filtration, and cooling.
The Communist Chinese captured 39 P-51s from the Nationalists while they were retreating to Taiwan. In August 1949, the People's Liberation Army Air Force formed its first P-51 squadron at Beijing Nanyuan Airport and were tasked of the defending Beijing's airspace from Nationalist Air Force aircraft. On 1 October 1949, when Mao Zedong proclaimed the founding of the People's Republic of China, nine P-51s conducted a fly-past during the military parade in Beijing. By 1950, when Soviet Union began supplying modern military equipment to China, surviving P-51s were relegated to PLAAF's aviation school and 13 P-51s were modified as two-seat trainers. By September 1953, most P-51s were retired from service and only eight P-51s remained in service to teach Ilyushin Il-10 pilots on how to taxi aircraft. Costa Rica The Costa Rican Air Force flew four P-51Ds from 1955 to 1964. Cuba In November 1958, three US-registered civilian P-51D Mustangs were illegally flown separately from Miami to Cuba, on delivery to the rebel forces of the 26th of July Movement, then headed by Fidel Castro during the Cuban Revolution. One of the Mustangs was damaged during delivery and none of them were used operationally. After the success of the revolution in January 1959, with other rebel aircraft plus those of the existing Cuban government forces, they were adopted into the Fuerza Aérea Revolucionaria. Due to increasing US restrictions and lack of spares and maintenance experience, they never achieved operational status.
Sources: en.wikipedia.org
One method based on the chemical constitution of the non-glucose part of the molecules has been proposed that posits four groups: (1) alkyl derivatives, (2) benzene derivatives, (3) styrolene derivatives, and (4) anthracene derivatives. A group may also be constructed to include the cyanogenic glucosides, i.e. those containing prussic acid. Alternate classifications follow a botanical classification, which has several advantages; in particular, plants of allied genera contain similar compounds. This article follows the chemical classification and discusses only the more important compounds.
== Mediated apoptosis == Once inside the target cell, granzyme B can cleave and activate initiator caspases 8 and 10, and executioner caspases 3 and 7 which trigger apoptosis. Caspase 7 is the most sensitive to granzyme B and caspases 3, 8, and 10 are only cleaved to intermediate fragments and need further cleavage for full activation. Granzyme B can also cleave BID leading to BAX/BAK oligomerisation and cytochrome c release from the mitochondria. Granzyme B can cleave ICAD leading to DNA fragmentation and the laddering pattern associated with apoptosis. Granzyme B has a potential of over 300 substrates and can cleave Mcl-1 in the outer mitochondrial membrane relieving its inhibition of Bim. Bim stimulates BAX/BAK oligomerisation, mitochondrial membrane permeability and apoptosis. Granzyme B can also cleave HAX1 (Hs-1 associated protein X-1) to facilitate mitochondria polarisation. Granzyme B can also generate a cytotoxic level of mitochondrial reactive oxygen species (ROS) to mediate cell death. The caspase independent pathways of cell death are thought to have arisen to overcome viruses that can inhibit caspases and prevent apoptosis.
=== Direct intensity === This method adds to the dilution to threshold method by considering the perceived intensity of the compounds as well. Assessors can report this based on a predetermined scale. The posterior intensity method measures the maximum intensity perceived for each eluting compound. A panel of assessors is recommended to be used to obtain an averaged signal. On the other hand, the dynamic time-intensity method measures the intensity at different points in time starting from the time of elution, allowing a continuous measurement of onset, maximum, and decline of the odour intensity. This is used in the Osme (Greek word for odour) method developed in 1992 by Da Silva. An aromagram can then be constructed in a similar way as an FID chromatogram whereby intensity is plotted as a function of retention time. The peak height corresponds to the maximum intensity perceived whereas the peak width corresponds to the duration of the odour perceived. The time requirement maybe high for this particular method regarding the essentials of assessor training, as lack of training may result in inconsistencies in scale usage. However, with a trained panel of assessors, the analysis can be done in a relatively short amount of time with high precision.
==== Libya ==== The mummified remains of an infant were discovered during an expedition by archaeologist Fabrizio Mori to Libya during the winter of 1958–1959 in the natural cave structure of Uan Muhuggiag. After curious deposits and cave paintings were discovered on the surfaces of the cave, expedition leaders decided to excavate. Uncovered alongside fragmented animal bone tools was the mummified body of an infant, wrapped in animal skin and wearing a necklace made of ostrich egg shell beads. Professor Tongiorgi of the University of Pisa radiocarbon-dated the infant to between 5,000 and 8,000 years old. A long incision located on the right abdominal wall, and the absence of internal organs, indicated that the body had been eviscerated post-mortem, possibly in an effort to preserve the remains. A bundle of herbs found within the body cavity also supported this conclusion. Further research revealed that the child had been around 30 months old at the time of death, though sex could not be determined due to poor preservation of the sex organs.
=== Sheep === In sheep, ketosis, evidenced by hyperketonemia with beta-hydroxybutyrate in blood over 0.7 mmol/L, is referred to as pregnancy toxemia. This may develop in late pregnancy in ewes bearing multiple fetuses and is associated with the considerable metabolic demands of the pregnancy. In ruminants, because most glucose in the digestive tract is metabolized by rumen organisms, glucose must be supplied by gluconeogenesis. Pregnancy toxemia is most likely to occur in late pregnancy due to metabolic demand from rapid fetal growth and may be triggered by insufficient feed energy intake due to weather conditions, stress or other causes. Prompt recovery may occur with natural parturition, Caesarean section or induced abortion. Prevention through appropriate feeding and other management is more effective than treatment of advanced stages of pregnancy toxemia.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.